SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Microsoft Unveils Massive Global AI Investments, Prioritizing India’s Rapidly Growing Digital Market 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
ADB Approves $400 Million Loan to Boost Ease of Doing Business in the Philippines 
Samsung SDI Secures Major LFP Battery Supply Deal in the U.S. 
EssilorLuxottica Bets on AI-Powered Smart Glasses as Competition Intensifies 
ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
EU Court Cuts Intel Antitrust Fine to €237 Million Amid Long-Running AMD Dispute 
GameStop Misses Q3 Revenue Estimates as Digital Shift Pressures Growth 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Westpac Director Peter Nash Avoids Major Investor Backlash Amid ASX Scrutiny 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
Gulf Sovereign Funds Unite in Paramount–Skydance Bid for Warner Bros Discovery 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
Air Transat Reaches Tentative Agreement With Pilots, Avoids Strike and Restores Normal Operations 
Activist investor Starboard Value has fully exited its position in Pfizer, marking the end of a high-profile effort to pressure the pharmaceutical giant into boosting its flagging share price. According to a recent 13-F regulatory filing, Starboard sold approximately 8.5 million Pfizer shares during the third quarter, unwinding a stake that once totaled 15.4 million shares at the end of Q4 2024.
Starboard initially made waves when it disclosed a roughly $1 billion investment in Pfizer a year ago, stepping in at a time when the company’s stock was trading at roughly half its peak during the pandemic. The fund’s founder, Jeffrey Smith, was outspoken about Pfizer’s performance, arguing at an industry event that the board needed to hold management accountable for persistent underperformance and weak market confidence.
Despite its push for governance and operational improvements, Starboard’s campaign struggled to gain lasting traction. The firm had approached former Pfizer executives—including former CEO Ian Read—for strategic guidance, but discussions reportedly stalled. Pfizer’s current market value sits around $142 billion, a decline from roughly $162 billion when Starboard’s involvement was first revealed in October 2024.
Starboard, known for its aggressive activist strategies, has been active across several industries this year, taking positions in companies such as TripAdvisor, Rogers, and BILL Holdings, where it secured a board seat shortly after investing. However, its Pfizer exit marks a notable retreat from what was once one of its most closely watched campaigns.
The same filing also revealed that Starboard fully divested from Fortrea Holdings, a contract research organization spun off from LabCorp in 2023. The hedge fund sold 2.5 million Fortrea shares during the third quarter. Since Starboard disclosed its investment in October 2023, Fortrea’s share price has fallen nearly 50%, adding another setback to the fund’s recent positions.
Starboard declined to comment on the latest disclosures.
